CLINICAL TRIALS

 

Our Urology Health Bryn Mawr location is actively engaged in clinical research.  In the past, this office has participated in trials of new medications for Prostate Cancer, BPH, Prostatitis, Testosterone Replacement Therapy, Bladder Cancer, Erectile Dysfunction and Overactive Bladder.

 

If you are interested in participating or would like more information on these trials, please click to contact the Urology Health Bryn Mawr location or call 610-525-2515.

 

ACTIVE TRIALS

Currently, we are enrolling patients in the following active trials:

ARAMIS 3104007 (BAYER)
A Study to evaluate Efficacy and safety study of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer
Primary Objective: To demonstrate superiority of ODM-201 over placebo in metastasis-free survival in patients with high-risk non-metastatic castration-resistant prostate cancer.


PCR 3003 (JANSSEN)
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Metastatic Hormone sensitive Prostate Cancer (mHSPC)
Primary Objective: To determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in subjects with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy (RT) results in an improvement of metastasis-free survival (MFS).


AQX-1125-301 (AQUINOX)
The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by 14 or 40-Week Extension Periods
Primary Objective: To determine if AQX-1125, an oral, small molecule, anti-inflammatory agent that activates SHIP1 protein reduces symptoms of interstitial cystitis/bladder pain syndrome (IC/BPS).


DENDREON P12-1
A study to evaluate characteristics predictive of a positive imaging study for distant metastases in patients with castration-resistant prostate cancer
Primary Objective: To evaluate characteristics predictive of a baseline imaging study positive for distant metastases (M1) in patients with castration-resistant prostate cancer (CRPC) and no known metastases.


VIVENTIA
An Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Subjects with Non-Muscle-Invasive Carcinoma in Situ (CIS) and/or High-Grade Papillary Disease of the Bladder Previously Treated with Bacillus Calmette-Guérin (BCG)
Primary Objective: To assess the efficacy and tolerability of Vicinium when administered as a monotherapy intravesical instillation in subjects with non-muscle-invasive bladder cancer - CIS, high-grade Ta or any grade T1 papillary disease or CIS plus papillary disease - who failed previous treatment with BCG.

 

Dendreon P12-1

A study to evaluate characteristics predictive of a positive imaging study for distant metastages in patients with castrate-resistant prostate cancer.

Primary Objective: To evaluate characteristics predictive of a baseline imaging study positive for distant metastases in patients with castration-resistant prostate cancer and no known M1.

Study Population:  Men with castration-resistant prostate cancer and no known M1 disease who are at least 18 years of age at the time of screening are eligible.

Principal Investigator: Guy Bernstein, M.D.

 

Aramis 3104007

A study to evaluate the efficacy and safety study of ODM-201 in men with high-risk non-metastatic (m0) casteration-resistant prostate cancer.

Primary Objective: To demonstrate superiority of ODM-201 over placebo in metastatsis-free survival in patients with high-risk non-metastatic casteration-resistant prostate cancer.

Study Population:  Men with castration-resistant prostate cancer (rising PSA on hormone therapy) and no known M1 disease who are at least 18 years of age at the time of screening are eligible.

Principal Investigator: Guy Bernstein, M.D.

 

Spartan ARN-509-003

A study to evaluate the efficacy and safety study of ARN-509 in men with non-mestatic (M0) casteration-resistant prostate cacner.

Primary Objective: To demonstrate superiority in the metastasis-free survival of men with high risk NM-CRPC treated with ARN-509 over placebo.

Study Population:  Men with castration-resistant prostate cancer (rising PSA on hormone therapy) and no known M1 disease who are at least 18 years of age at the time of screening are eligible.

Principal Investigator: Guy Bernstein, M.D.
 

 Sotio SP005

A study to evaluate the efficacy and safety of DCVAC/PCa versus placedo in men with metastatic castration resistant prostate cancer eligible for 1st line chemotherapy.

Primary Objective: To demonstrate superiority of treatment with DCVAC/PCa in addition to SOC (docetaxel plus prednisone) over placebo in addition to SOC (docetaxel plus prednisone) in men with mCRPC as measured by overall survival.

Study Population:  Men with casteration-resistant prostate cancer (rising PSA on hormone therapy) and know M1 disease who are eligible for begin chemotherapy.

Principal Investigator: Guy Bernstein, M.D.

  

Pacific Edge Cx Bladder

A study to evaluate the Cx Bladder test in the primary detection and initial diagnosis of bladder cancer.

Primary Objective: To demonstrate the clinical utility of the Cx Bladder test within urological patients presenting with macroscopic hematuria who are undergoing cystoscopy for the investigation of suspected bladder cancer.

Study Population:  Patients with no history of urinary tract cancer who present with gross hematuria and are scheduled to undergo cystoscopy.

Principal Investigator: Guy Bernstein, M.D.

 

 UROLOGY HEALTH OFFICE LOCATIONS

ABINGTON
1235 Old York Road
Abington, PA 19001
215-517-1100

BRYN MAWR
245 South Bryn Mawr Avenue
Bryn Mawr, PA 19010
610-525-2515

CONCORDVILLE
1020 Baltimore Pike
Glen Mills, PA 19342
610-744-2844

DOYLESTOWN
599 West State Street
Doylestown, PA 18901
215-230-9070

DREXEL HILL
2100 Keystone Avenue
Drexel Hill, PA 19026

610-259-3000

HORSHAM
3 Village Road
Horsham, PA 19044
215-884-7114

HUNTINGDON VALLEY
1800 Byberry Road

Suite 1203
Huntingdon Valley, PA 19006
215-947-4105

MEDIA
1088 West Baltimore Pike

HCC II, Suite 2304
Media, PA 19063
610-744-2844

PAOLI
4 Industrial Boulevard

Suite 180
Paoli, PA 19301
610-525-2515

PHILA - CHESTNUT HILL

8815 Germantown Avenue

Suite 21
Philadelphia, PA 19118
215-242-8260

PHILA - NAZARETH
2701 Holme Avenue
Philadelphia, PA 19152
215-335-3535

PHILA - ROXBOROUGH

5735 Ridge Avenue
Philadelphia, PA 19128
215-482-1141

PLYMOUTH MEETING
400 Davis Drive, Suite 200
Plymouth Meeting, PA 19462

215-482-1141

WEST GROVE
1011 West Baltimore Pike
West Grove, PA 19390
610-869-6851

WYNNEWOOD
100 Lancaster Ave, East 361
Wynnewood, PA 19096
610-649-6420

WILMINGTON, DELAWARE
701 North Clayton Street
Wilmington, DE 19805
610-869-6851
 

 

   


 SURGERY CENTER LOCATIONS                             UH PROSTATE CANCER CENTER

HUNTINGDON VALLEY
1800 Byberry Road

Suite 1204
Huntingdon Valley, PA 19006

215-947-4105

 

PAOLI

4 Industrial Boulevard

Suite 175
Paoli, PA 19301
484-320-7700

CANCER CENTER
400 Davis Drive

Suite 200
Plymouth Meeting, PA 19462
610-825-2151

CORPORATE OFFICE
140 West Germantown Pike

Suite 250
Plymouth Meeting, PA 19462
484-530-0205

BILLING OFFICE
P.O. Box 1287
Blue Bell, PA 19422
484-530-0203

Urology Health Specialists, LLC is not affiliated with Universal Health Services, Inc. or UHS of Delaware, Inc.